Qiagen Secures DoD Contract To Boost Production Capacity For NeuMoDx

Qiagen NV QGEN won a U.S. government contract to increase the production capacity for consumables used on its NeuMoDx 96 and 288 integrated PCR testing systems.
Related Link: Qiagen's COVID-19 Antigen Test Gets FDA Emergency Use Approval
Qiagen was awarded a $3.4 million contract by the U.S. Department of Defense (DOD), on behalf of and in coordination with the Department of Health and Human Services (HHS), to expand production capacity for COVID-19 tests running on NeuMoDx instruments at its site in Ann Arbor, Michigan.
By the end of March 2022, Qiagen plans to scale production to more than 16 million tests per year, up from the current level of about 10 million.
This contract follows an announcement in August 2021 that DoD and HHS had awarded Qiagen a contract for approximately $600,000 to expand production capacity for chemical reagents.
Price Action: QGEN stock is down 0.66% at $51.34 during the premarket session on the last check Friday.